Objective: To compare the occurrence of hypoglycemia during hemodialysis in chronic kidney disease diabetic patients who present different levels of pre-dialysis glycemia both when using dialysis solutions with and without glucose. Subjects and methods: Twenty type 2 diabetic patients in maintenance hemodialysis were submitted to three dialysis sessions (at a 7-day interval each) with dialysis solutions without glucose, with glucose at 55 mg/dL, and at 90 mg/dL subsequently. Blood glucose levels were measured immediately pre-dialysis and at 4 moments during the session, and values under 70 mg/dL were considered as hypoglycemia. Results: Average pre-dialysis glycemia was lower in those who presented intra-dialytic hypoglycemia than in those who did not, both in glucose-free (140.4 ± 50.7 vs. 277.7 ± 91.0 mg/dL; p = 0.005; 95%CI: 46.4 to 228.1) and in glucose 55 mg/dL (89.5 ± 10.6 vs. 229.7 ± 105.0 mg/dL; p < 0.05; 95%CI: 9.8 to 270.5). In patients with pre-dialysis glycemia under 140 mg/dL, average intradialytic glycemia was significantly lower than pre-dialysis glycemia only when using glucose-free dialysate (p < 0.0001; 95%CI: 29.9 to 56.0 -t-test). Hypoglycemia during dialysis was observed only when using glucose-free or glucose-poor dialysis solutions. Conclusions: The use of glucose-free or glucose-poor dialysis solution presents a high risk of intradialytic hypoglycemia in diabetic renal patients, especially in those with presumed better glycemic control. Arch Endocrinol Metab. 2015;59(2):137-40
INTRODUCTION
A symptomatic hypoglycemia (HG) during hemodialysis (HD) has been reported in chronic kidney disease (CKD) patients since more than a decade ago (1) , and it is common in diabetic (DM) individuals when dialysis is performed with a glucose-free dialysis solution (2, 3) . Moreover, the use of glucose-added dialysate showed a significant reduction and even the absence of intradialytic HG (3) , and nowadays its use is indicated and largely diffused (4) . Recently, we published a study in which we compared the occurrence of HG during dialysis with different levels of glucose (5) . Now we revised these data in order to verify the hypothesis that intradialytic HG episodes in DM patients could be related to pre-dialysis serum glucose levels.
SUBJECTS AND METHODS
This study was approved by the Ethics Committees in Research of Universidade Luterana do Brasil (ULBRA), and all participants signed an informed consent form.
Twenty CKD patients in stable maintenance HD were randomly selected among all 34 adult type 2 diabetic (T2DM) individuals from an HD unit. They should be free from any hospitalization or infectious event in the past 4 weeks, and BMI should be over 20 kg/m 2 . The patients were submitted to three mid-week HD sessions with a 7-day interval, using different glucose concentrations in the dialysate fluid -first with a glucose-free (GluZERO), later with glucose 55 mg/dL (Glu55), and then with 90 mg/dL (Glu90). In each phase, plasma glucose levels were measured immediately pre-dialysis (pre-HD glycemia), and in four standardized moments during the session (intra-HD glycemia) -at 30, 60, 150, and 240 min. Hypoglycemia was considered as a blood glucose level under 70 mg/dL even without symptoms, as stated in previous studies (2, 3) . Other details of the study were decribed in the original article (5 For the present analysis, we compared pre-HD with intra-HD average glycemia in each phase, both in those patients who presented HG episodes as in those without HG. We also studied specifically those patients with pre-HD glycemia under 140 mg/dL in each phase, comparing pre-HD to intra-HD average glycemia in each phase.
Bivariate statistical analysis was performed using GraphPad InStat 3.05 (GraphPad Software, San Diego, California, USA). Student's t-test was used to compare continuous variables. Statistical significance was set at P < 0.05.
RESULTS
The 20 patients' age was 56.3 ± 11.8 yrs-old (mean ± SD). Twelve (60%) were male. All of them were on dialysis for an average of 56.3 months and presented the diagnosis of diabetes for more than 7 years.
Five patients in GluZERO and three patients in Glu55 presented seven and five HG episodes respectively, none during Glu90.
For all individuals, mean intradialytic glycemia was significantly lower than pre-HD glycemia in each of the 3 phases, a finding more pronounced in GluZERO (151.9 ± 70.2 vs. 243.4 ± 101.8 mg/dL).
Average pre-HD glycemia was lower in those who presented intra-HD episodes of HG than in those who did not, both in GluZERO (140.4 ± 50.7 vs. 277.7 ± 91.0 mg/dL; p = 0.005) and in Glu55 (89.5 ± 10.6 vs. 229.7 ± 105.0 mg/dL; p < 0.05) ( Table 1) .
Among those with pre-HD glycemia under 140 mg/dL (respectively five, six, and five patients in Glu-ZERO, Glu55, and Glu90), mean intra-HD glycemia was significantly lower only in phase GluZERO (p = 0.0015; t test) ( Table 2 ).
DISCUSSION
It is well established, especially in DM individuals, that asymptomatic hypoglycemia is usual during hemodialysis with glucose-free dialysis solution, and that a glucose-added dialysate prevents these events (2,3,5-7). However, to the best of our knowledge, no one has previously studied the relationship of these hypoglycemic events with pre-HD blood glucose levels.
We observed that the occurrence of HG during the dialysis session is related to blood glucose level significantly lower, though normal, at the begining of dialysis (Table 1) . Moreover, when considering only those patients with pre-HD blood glucose level under 140 mg/dL, who are supposedly more prone to HG during dialysis, we found intra-HD glycemia significantly lower than pre-HD glycemia only during glucose-free dialysis (Table 2 ). These data seem to indicate a higher risk of intradialytic HG for DM individuals who presumably present the best glycemic control, especially when in glucose-free dialysis. Further, we found a significant Table 1 . Glycemia (pre-HD and intra-HD -mean ± SD; mg/dL) in those with and without HG during each phase Table 2 . Pre-HD and intra-HD glycemia (mean±SD; mg/dL) in patients with pre-HD glycemia < 140 mg/dL in each phase decrement of blood glucose levels during dialysis (Table 1), which could be due, at least in part, to a loss of glucose in the dialysate (1-3).
All the above highlight the risk of using dialysis solution without glucose in DM patients.
As the maintenance of good glycemic control in DM patients on dialysis is related to lower mortality and better quality of life (8) (9) (10) (11) (12) (13) , it seems fundamental that this control must be in line with a dialysis procedure that precludes HG.
In the early days of dialytic therapy, glucose was present in hemodialysis fluid. Later, this was followed by the wide use of glucose-free solutions in order to avoid the risk of bacterial contamination and for cost reduction (4, 14) . This practice became usual despite reports, since that time, about possible deleterious effects related to the lack of glucose in the dialysis solution (15) (16) (17) . However, this matter was recently resumed, and the presence of glucose in dialysate became widely advisable to prevent frequent symptom-free HG and its consequences in DM patients, as the involvement of the central nervous system (3, 4) . The frequent repetition of these asymptomatic events leads to a cerebral adaptation to low blood glucose levels, and this has been attributed as the cause of the lack of symptoms (18) . In consequence, these patients are submitted to the risk of a progressively compromised cognitive function (19) (20) (21) . Ramirez and cols. (16) , in 1986, first called attention to electroencephalographic abnormalities when using glucose-free hemodialysis solutions. Recently, Cui and cols. used metabonomics to compare the metabolic properties of maintenance hemodialysis patients with and without glucose in dialysate. Their results showed that glucose-added dialysate was more efficient than glucose-free fluid in providing energy to the central nervous system (22) .
In our study, the small number of patients, the lack of information about some clinical data (for instance, the presence of autonomic neuropathy, and a proper method of regular glycemic control), and also some characteristics peculiar to this kind of study (e.g., the different ranges of time between daily meals and the start of the dialysis session; and the individual administration schedule of insulin or oral hypoglycemic drugs) -all may have caused some influence on our results. Nevertheless, the strength of our data relies on the fact of being obtained under usual daily clinical conditions, this way reflecting the reality of regular hemodialysis treatment in diabetics.
In conclusion, T2DM patients with lower, though normal, pre-HD glycemia seem to present higher risk of developing intradialytic HG when using a dialysis solution without glucose or with low concentration of glucose. These findings allow to suppose that diabetic CKD patients who are in best glycemic control present higher risk of HG episodes during HD sessions with a glucose-free (or a glucose-poor) dialysis solution. In this way, while optimizing diabetes treatment and glycemic control, we would be providing a worse dialysis therapy if a glucose-free or glucose-poor dialysis solution was used. Finally, these data strengthens the importance of an adequate level of glucose in the composition of hemodialysis solution.
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